Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Rineke B. L. Leys"'
Autor:
Kazimierz Groen, Febe Smits, Kazem Nasserinejad, Mark‐David Levin, Josien C. Regelink, Gert‐Jan Timmers, Esther G. M. deWaal, Matthijs Westerman, Gerjo A. Velders, Koen deHeer, Rineke B. L. Leys, Roel J. W. vanKampen, Claudia A. M. Stege, Maarten R. Seefat, Inger S. Nijhof, Ellen van derSpek, Saskia K. Klein, Niels W. C. J. van deDonk, Paula F. Ypma, Sonja Zweegman
Publikováno v:
HemaSphere, Vol 8, Iss 7, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/35ff82dc826f4e589fe20f0d84490eb9
Autor:
Klaas G. van der Hem, Kaz Groen, Niels W.C.J. van de Donk, Amanda C. Dijk, Nicole C. H. P. van der Burg-de Graauw, Mark-David Levin, Kazem Nasserinejad, Henriette Levenga, Paula F. Ypma, Aart Beeker, L. Strobbe, Inger S. Nijhof, Harm Sinnige, Claudia A.M. Stege, Saskia K. Klein, Roel J. W. van Kampen, Gerjo A. Velders, Ad Koster, Mels Hoogendoorn, Rineke B. L. Leys, Matthijs Westerman, Gert-Jan Timmers, Pieter Sonneveld, Marjan A. Davidis-van Schoonhoven, Sonja Zweegman, Nazik Durdu-Rayman, Matthijs H Silbermann, Ellen van der Spek, Yavuz M. Bilgin
Publikováno v:
Leukemia, 35(9), 2715-2719. Nature Publishing Group
Stege, C A M, Nasserinejad, K, Klein, S K, Timmers, G J, Hoogendoorn, M, Ypma, P F, Nijhof, I S, Velders, G A, Strobbe, L, Durdu-Rayman, N, Westerman, M, Davidis-van Schoonhoven, M A, van Kampen, R J W, Beeker, A, Koster, A, Dijk, A C, van de Donk, N W C J, van der Spek, E, Leys, R B L, Silbermann, M H, Groen, K, van der Burg-de Graauw, N C H P, Sinnige, H A M, van der Hem, K G, Levenga, H, Bilgin, Y M, Sonneveld, P, Levin, M D & Zweegman, S 2021, ' Improving the identification of frail elderly newly diagnosed multiple myeloma patients ', Leukemia, vol. 35, no. 9, pp. 2715-2719 . https://doi.org/10.1038/s41375-021-01162-z
Stege, C A M, Nasserinejad, K, Klein, S K, Timmers, G J, Hoogendoorn, M, Ypma, P F, Nijhof, I S, Velders, G A, Strobbe, L, Durdu-Rayman, N, Westerman, M, Davidis-van Schoonhoven, M A, van Kampen, R J W, Beeker, A, Koster, A, Dijk, A C, van de Donk, N W C J, van der Spek, E, Leys, R B L, Silbermann, M H, Groen, K, van der Burg-de Graauw, N C H P, Sinnige, H A M, van der Hem, K G, Levenga, H, Bilgin, Y M, Sonneveld, P, Levin, M D & Zweegman, S 2021, ' Improving the identification of frail elderly newly diagnosed multiple myeloma patients ', Leukemia, vol. 35, no. 9, pp. 2715-2719 . https://doi.org/10.1038/s41375-021-01162-z
Autor:
Mels Hoogendoorn, Rineke B L Leys, Dana A. Chitu, Okke de Weerdt, Hanneke C. Kluin-Nelemans, Eva de Jongh, Rien van Marwijk Kooij, Robby E. Kibbelaar, Mars B. van 't Veer, Michel van Gelder, Monique C. Minnema, Marie Josee Kersten, Josée M. Zijlstra, Daphne de Jong, Jeanette K. Doorduijn, M.A. MacKenzie, Tjeerd J. F. Snijders, Pieternella J. Lugtenburg, Lara H Böhmer
Publikováno v:
Doorduijn, J K, Zijlstra, J M, Lugtenburg, P J, Kersten, M J, Böhmer, L H, Minnema, M C, MacKenzie, M A, van Marwijk Kooij, R, de Jongh, E, Snijders, T J F, de Weerdt, O, van Gelder, M, Hoogendoorn, M, Leys, R B L, Kibbelaar, R E, de Jong, D, Chitu, D A, Van’t Veer, M B & Kluin-Nelemans, H C 2020, ' Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial ', British Journal of Haematology, vol. 190, no. 3, pp. 385-393 . https://doi.org/10.1111/bjh.16567
British Journal of Haematology, 190(3), 385-393. Wiley
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell
British Journal of Haematology, 190, 3, pp. 385-393
British Journal of Haematology
British Journal of Haematology, 190, 385-393
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell Publishing Ltd
British journal of haematology, 190(3), 385-393. Wiley-Blackwell
British Journal of Haematology, 190(3), 385-393. Wiley
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell
British Journal of Haematology, 190, 3, pp. 385-393
British Journal of Haematology
British Journal of Haematology, 190, 385-393
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell Publishing Ltd
British journal of haematology, 190(3), 385-393. Wiley-Blackwell
Contains fulltext : 225496.pdf (Publisher’s version ) (Open Access) Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most p
Autor:
Sonja Zweegman, Zweegman, Claudia A M Stege, A, Haukås, Einar, Schjesvold, Fredrik H, Mark-David Levin, Levin, Waage, Anders, Rineke B L Leys, B, Saskia K Klein, K, Szatkowski, Damian Lukasz, Per Axelsson, Axelsson, Trung Hieu Do, Hieu, Dorota Knut-Bojanowska, Knut-Bojanowska, Ellen van der Spek, van, Asta Svirskaite, Svirskaite, Anja Klostergaard, Klostergaard, Morten Salomo, Salomo, Celine Blimark, Blimark, Paula F Ypma, F, Ulf-Henrik Mellqvist, Mellqvist, Pino J Poddighe, J, Marian Stevens-Kroef, Stevens-Kroef, Niels W C J van de Donk, W, Pieter Sonneveld, Sonneveld, Markus Hansson, Hansson, Bronno van der Holt, van, Niels Abildgaard, Abildgaard
Externí odkaz:
https://hdl.handle.net/11250/2733197
Autor:
Ellen van der Spek, Morten Salomo, Damian L. Szatkowski, Einar Haukås, Paula F. Ypma, Per Axelsson, Saskia K. Klein, Pino J Poddighe, Sonja Zweegman, Fredrik Schjesvold, Mark-David Levin, Marian Stevens-Kroef, Asta Svirskaite, Trung Hieu Do, Pieter Sonneveld, Markus Hansson, Claudia A.M. Stege, Dorota Knut-Bojanowska, Celine Blimark, Anja Klostergaard, Rineke B. L. Leys, Niels Abildgaard, Niels W.C.J. van de Donk, Bronno van der Holt, Anders Waage, Ulf-Henrik Mellqvist
Publikováno v:
Haematologica, 105, 12, pp. 2879-82
Zweegman, S, Stege, C A M, Haukas, E, Schjesvold, F H, Levin, M-D, Waage, A, Leys, R B L, Klein, S K, Szatkowski, D, Axelsson, P, Hieu Do, T, Knut-Bojanowska, D, van der Spek, E, Svirskaite, A, Klostergaard, A, Salomo, M, Blimark, C, Ypma, P F, Mellqvist, U-H, Poddighe, P J, Stevens-Kroef, M, van de Donk, N W C J, Sonneveld, P, Hansson, M, van der Holt, B & Abildgaard, N 2020, ' Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial ', Haematologica, vol. 105, no. 12, pp. 2879-2882 . https://doi.org/10.3324/haematol.2019.240374
Haematologica, 105(12), 2879-2882. Ferrata Storti Foundation
Haematologica, 105, 2879-82
Haematologica
Sonja Zweegman, Z, Claudia A M Stege, A M S, Einar Haukas, H, Fredrik H Schjesvold, H S, Mark-David Levin, L, Anders Waage, W, Rineke B L Leys, B L L, Saskia K Klein, K K, Damian Szatkowski, S, Per Axelsson, A, Trung Hieu Do, H D, Dorota Knut-Bojanowska, K-B, Ellen van der Spek, V D S, Asta Svirskaite, S, Klostergaard, A, Morten Salomo, S, Celine Blimark, B, Paula F Ypma, F Y, Ulf-Henrik Mellqvist, M, Pino J Poddighe, J P, Marian Stevens-Kroef, S-K, Niels W C J van de Donk, W C J V D D, Pieter Sonneveld, S, Markus Hansson, H, Bronno van der Holt, V D H & Niels Abildgaard, A 2020, ' Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial ', Haematologica, vol. 105, no. 12, pp. 2879-2882 . https://doi.org/10.3324/haematol.2019.240374
Zweegman, S, Stege, C A M, Haukas, E, Schjesvold, F H, Levin, M-D, Waage, A, Leys, R B L, Klein, S K, Szatkowski, D, Axelsson, P, Hieu Do, T, Knut-Bojanowska, D, van der Spek, E, Svirskaite, A, Klostergaard, A, Salomo, M, Blimark, C, Ypma, P F, Mellqvist, U-H, Poddighe, P J, Stevens-Kroef, M, van de Donk, N W C J, Sonneveld, P, Hansson, M, van der Holt, B & Abildgaard, N 2020, ' Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial ', Haematologica, vol. 105, no. 12, pp. 2879-2882 . https://doi.org/10.3324/haematol.2019.240374
Haematologica, 105(12), 2879-2882. Ferrata Storti Foundation
Haematologica, 105, 2879-82
Haematologica
Sonja Zweegman, Z, Claudia A M Stege, A M S, Einar Haukas, H, Fredrik H Schjesvold, H S, Mark-David Levin, L, Anders Waage, W, Rineke B L Leys, B L L, Saskia K Klein, K K, Damian Szatkowski, S, Per Axelsson, A, Trung Hieu Do, H D, Dorota Knut-Bojanowska, K-B, Ellen van der Spek, V D S, Asta Svirskaite, S, Klostergaard, A, Morten Salomo, S, Celine Blimark, B, Paula F Ypma, F Y, Ulf-Henrik Mellqvist, M, Pino J Poddighe, J P, Marian Stevens-Kroef, S-K, Niels W C J van de Donk, W C J V D D, Pieter Sonneveld, S, Markus Hansson, H, Bronno van der Holt, V D H & Niels Abildgaard, A 2020, ' Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial ', Haematologica, vol. 105, no. 12, pp. 2879-2882 . https://doi.org/10.3324/haematol.2019.240374
Contains fulltext : 229254.pdf (Publisher’s version ) (Open Access)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0355ddccdcad64c6d512a5e716350e5d
https://hdl.handle.net/2066/229254
https://hdl.handle.net/2066/229254
Autor:
Annette W.G. van der Velden, Bronno van der Holt, Gerard M. J. Bos, Harm Sinnige, Anders Waage, Ulf-Henrik Mellqvist, Damian L. Szatkowski, Klaas G. van der Hem, Markus Hansson, Peter Gimsing, Pieter Sonneveld, Juleon Coenen, Morten Salomo, Rineke B. L. Leys, Einar Haukås, Lene Kongsgaard Nielsen, Sonja Zweegman, Mark-David Levin, Saskia K. Klein, Niels Abildgaard, Heleen Visser-Wisselaar, Wendy Deenik, Maja Hinge, Matthijs Westerman, Birgit I. Lissenberg-Witte, Claudia A.M. Stege, Niels W.C.J. van de Donk
Publikováno v:
SSRN Electronic Journal.
Background: The overall survival of patients with Multiple Myeloma has improved due to effective, often continuous, therapy. However, knowledge on the impact of long term treatment on health-related quality of life (HRQoL) is limited. Methods: The HO
Autor:
Bronno van der Holt, Anders Waage, Niels W.C.J. van de Donk, E. (Vera) J. M. Mattijssen, M. (Rineke) B. L. Leys, Annette W. G. van der Velden, Mark-David Levin, Harm Sinnige, Klaas G. van der Hem, Morten Salomo, Bea Tanis, Einar Haukås, Ulf-Henrik Mellqvist, Matthijs Westerman, Rolf Brouwer, Pieter Sonneveld, Saskia K. Klein, Astrid Gruber, Gerard M. J. Bos, Marian Stevens-Kroef, Markus Hansson, Damian L. Szatkowski, Wendy Deenik, Torben Plesner, Sonja Zweegman, Marc Durian, Heleen Visser-Wisselaar, Juleon Coenen
Publikováno v:
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M R B L, Sinnige, H A M, Haukås, E, van der Hem, K G, Durian, M F, Mattijssen, E V J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127(9), 1109-1116. American Society of Hematology
Blood, 127(9), 1109-1116. The American Society of Hematology
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M B L, Sinnige, H A M, Haukas, E, van der Hem, K G, Durian, M F, Mattijssen, E J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127, 1109-16
Blood, 127, 9, pp. 1109-16
Blood, 127(9), 1109-1116. American Society of Hematology
Blood, 127(9), 1109-1116. The American Society of Hematology
Zweegman, S, van der Holt, B, Mellqvist, U-H, Salomo, M, Bos, G M J, Levin, M-D, Visser-Wisselaar, H, Hansson, M, van der Velden, A W G, Deenik, W, Gruber, A, Coenen, J L L M, Plesner, T, Klein, S K, Tanis, B C, Szatkowski, D L, Brouwer, R E, Westerman, M, Leys, M B L, Sinnige, H A M, Haukas, E, van der Hem, K G, Durian, M F, Mattijssen, E J M, van de Donk, N W C J, Stevens-Kroef, M J P L, Sonneveld, P & Waage, A 2016, ' Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma ', Blood, vol. 127, no. 9, pp. 1109-1116 . https://doi.org/10.1182/blood-2015-11-679415
Blood, 127, 1109-16
Blood, 127, 9, pp. 1109-16
The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma who are ineligible for stem cell transplantation. Long-term treatment with thalidomide is hampered by ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27be0ae01cb43dea87bdd45a3473c8b5
https://portal.findresearcher.sdu.dk/da/publications/767d554b-0302-426c-b3cf-03650e95cbc9
https://portal.findresearcher.sdu.dk/da/publications/767d554b-0302-426c-b3cf-03650e95cbc9